company background image
CAMX

CamurusOM:CAMX Stock Report

Market Cap

kr8.7b

7D

-7.1%

1Y

-21.8%

Updated

28 Nov, 2021

Data

Company Financials +
CAMX fundamental analysis
Snowflake Score
Valuation2/6
Future Growth6/6
Past Performance0/6
Financial Health5/6
Dividends0/6

CAMX Stock Overview

Camurus AB (publ), a pharmaceutical company, develops and commercializes pharmaceuticals for serious and chronic conditions in Europe, Australia, the United States, Japan, and internationally.

Rewards

Trading at 83.3% below our estimate of its fair value

Earnings are forecast to grow 58.66% per year

Risk Analysis

No risks detected for CAMX from our risk checks.

Camurus Competitors

Abeona Therapeutics

NasdaqCM:ABEO

US$74.4m

Price History & Performance

Summary of all time highs, changes and price drops for Camurus
Historical stock prices
Current Share Pricekr159.20
52 Week Highkr237.50
52 Week Lowkr141.00
Beta1.29
1 Month Change-1.36%
3 Month Change-19.52%
1 Year Change-21.77%
3 Year Change62.45%
5 Year Change34.35%
Change since IPO141.21%

Recent News & Updates

Sep 09
Companies Like Camurus (STO:CAMX) Can Afford To Invest In Growth

Companies Like Camurus (STO:CAMX) Can Afford To Invest In Growth

Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...

Shareholder Returns

CAMXSE PharmaceuticalsSE Market
7D-7.1%-5.3%-5.2%
1Y-21.8%-3.4%27.2%

Return vs Industry: CAMX underperformed the Swedish Pharmaceuticals industry which returned -3.4% over the past year.

Return vs Market: CAMX underperformed the Swedish Market which returned 27.1% over the past year.

Price Volatility

Is CAMX's price volatile compared to industry and market?
CAMX volatility
CAMX Average Weekly Movement5.3%
Pharmaceuticals Industry Average Movement7.7%
Market Average Movement6.5%
10% most volatile stocks in SE Market11.9%
10% least volatile stocks in SE Market3.8%

Stable Share Price: CAMX is not significantly more volatile than the rest of Swedish stocks over the past 3 months, typically moving +/- 5% a week.

Volatility Over Time: CAMX's weekly volatility (5%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
1991146Fredrik Tiberghttps://www.camurus.com

Camurus AB (publ), a pharmaceutical company, develops and commercializes pharmaceuticals for serious and chronic conditions in Europe, Australia, the United States, Japan, and internationally. The company offers Buvidal, a buprenorphine injection for the treatment of opioid dependence; and episil oral liquid, a medical device for the treatment of inflammatory and painful conditions in the oral cavity. Its products pipeline also includes Brixadi for opioid dependence; CAM2038 that is in phase III clinical trials for the treatment of chronic pain; CAM2029, which is in phase III clinical trials for the treatment of acromegaly and neuroendocrine tumors; and CAM2043 that is in Phase II clinical trials for treatment of pulmonary arterial hypertension and Raynaud’s phenomenon.

Camurus Fundamentals Summary

How do Camurus's earnings and revenue compare to its market cap?
CAMX fundamental statistics
Market Capkr8.69b
Earnings (TTM)-kr141.90m
Revenue (TTM)kr523.35m

16.6x

P/S Ratio

-61.3x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
CAMX income statement (TTM)
Revenuekr523.35m
Cost of Revenuekr69.67m
Gross Profitkr453.67m
Expenseskr595.57m
Earnings-kr141.90m

Last Reported Earnings

Sep 30, 2021

Next Earnings Date

Feb 16, 2022

Earnings per share (EPS)-2.60
Gross Margin86.69%
Net Profit Margin-27.11%
Debt/Equity Ratio0%

How did CAMX perform over the long term?

See historical performance and comparison

Valuation

Is Camurus undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: CAMX (SEK159.2) is trading below our estimate of fair value (SEK955.21)

Significantly Below Fair Value: CAMX is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: CAMX is unprofitable, so we can't compare its PE Ratio to the Swedish Pharmaceuticals industry average.

PE vs Market: CAMX is unprofitable, so we can't compare its PE Ratio to the Swedish market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate CAMX's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: CAMX is overvalued based on its PB Ratio (10.5x) compared to the SE Pharmaceuticals industry average (3.3x).


Future Growth

How is Camurus forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?

58.7%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: CAMX is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (0.3%).

Earnings vs Market: CAMX is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: CAMX's is expected to become profitable in the next 3 years.

Revenue vs Market: CAMX's revenue (34.1% per year) is forecast to grow faster than the Swedish market (5.3% per year).

High Growth Revenue: CAMX's revenue (34.1% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: CAMX's Return on Equity is forecast to be high in 3 years time (25.4%)


Past Performance

How has Camurus performed over the past 5 years?

-7.6%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: CAMX is currently unprofitable.

Growing Profit Margin: CAMX is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: CAMX is unprofitable, and losses have increased over the past 5 years at a rate of 7.6% per year.

Accelerating Growth: Unable to compare CAMX's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: CAMX is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (223.7%).


Return on Equity

High ROE: CAMX has a negative Return on Equity (-17.15%), as it is currently unprofitable.


Financial Health

How is Camurus's financial position?


Financial Position Analysis

Short Term Liabilities: CAMX's short term assets (SEK650.9M) exceed its short term liabilities (SEK197.7M).

Long Term Liabilities: CAMX's short term assets (SEK650.9M) exceed its long term liabilities (SEK20.8M).


Debt to Equity History and Analysis

Debt Level: CAMX is debt free.

Reducing Debt: CAMX has not had any debt for past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: CAMX has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if CAMX has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.


Dividend

What is Camurus's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate CAMX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate CAMX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if CAMX's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if CAMX's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of CAMX's dividend in 3 years as they are not forecast to pay a notable one for the Swedish market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

5.4yrs

Average management tenure


CEO

Fredrik Tiberg (58 yo)

18.83yrs

Tenure

kr9,621,000

Compensation

Mr. Fredrik Tiberg has been Independent Board Member of Amniotics AB (publ) since 2021. He has been the Chief Executive Officer and President of Camurus AB (publ) since 2003. He is also Head of Research at...


CEO Compensation Analysis

Compensation vs Market: Fredrik's total compensation ($USD1.06M) is above average for companies of similar size in the Swedish market ($USD721.79K).

Compensation vs Earnings: Fredrik's compensation has increased whilst the company is unprofitable.


Leadership Team

Experienced Management: CAMX's management team is seasoned and experienced (5.4 years average tenure).


Board Members

Experienced Board: CAMX's board of directors are considered experienced (3.5 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: CAMX insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Camurus AB (publ)'s employee growth, exchange listings and data sources


Key Information

  • Name: Camurus AB (publ)
  • Ticker: CAMX
  • Exchange: OM
  • Founded: 1991
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: kr8.693b
  • Shares outstanding: 54.60m
  • Website: https://www.camurus.com

Number of Employees


Location

  • Camurus AB (publ)
  • Ideon Science Park
  • Lund
  • Skåne County
  • 223 70
  • Sweden

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/11/28 18:47
End of Day Share Price2021/11/26 00:00
Earnings2021/09/30
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.